Version 1
: Received: 20 January 2024 / Approved: 22 January 2024 / Online: 22 January 2024 (10:02:04 CET)
How to cite:
Hana, C.; Thaw Dar, N. N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1
Hana, C.; Thaw Dar, N. N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints 2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1
Hana, C.; Thaw Dar, N. N.; Galo Venegas, M.; Vulfovich, M. Molecular Targeting of the Claudins Pathway.. Preprints2024, 2024011546. https://doi.org/10.20944/preprints202401.1546.v1
APA Style
Hana, C., Thaw Dar, N. N., Galo Venegas, M., & Vulfovich, M. (2024). Molecular Targeting of the Claudins Pathway.. Preprints. https://doi.org/10.20944/preprints202401.1546.v1
Chicago/Turabian Style
Hana, C., Michael Galo Venegas and Michel Vulfovich. 2024 "Molecular Targeting of the Claudins Pathway." Preprints. https://doi.org/10.20944/preprints202401.1546.v1
Abstract
Claudins are a family of 27 proteins that have an important role in the formation of tight junc-tions. They also have an important function in ions exchange, cell mobility, and in in the epitheli-al-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis.
Therapeutic targeting of claudins has been investigated to improve cancer outcomes. Recent evi-dence shows improved outcomes when combining monoclonal antibodies against Claudin 18.2 with chemotherapy for patients with gastroesophageal junction cancer. Currently Chimeric anti-gen receptor T-cells targeting Claudin 18 are under investigation.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.